Superstring Capital Management
Latest statistics and disclosures from Superstring Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CDTX, TERN, URGN, COGT, DVAX, and represent 39.96% of Superstring Capital Management's stock portfolio.
- Added to shares of these 10 stocks: URGN (+$15M), DVAX (+$8.1M), SION (+$7.4M), AXSM (+$6.8M), MNMD (+$5.7M), TSHA (+$5.4M), OCUL (+$5.1M), FOLD (+$5.0M), UTHR, RVMD.
- Started 29 new stock positions in MNMD, AXSM, UTHR, QNCX, RZLT, CLDX, DNTH, FULC, PVLA, SION.
- Reduced shares in these 10 stocks: TERN (-$14M), ETNB (-$5.7M), , BBIO, SMMT, IQV, , NKTR, INSM, BCAX.
- Sold out of its positions in BCAX, BBIO, CRBP, ETNB, NBP, INSM, IQV, KROS, NKTR, PTGX. RAPT, REGN, SNY, SRRK, SMMT, TECX, VIR, JAZZ, QURE.
- Superstring Capital Management was a net buyer of stock by $36M.
- Superstring Capital Management has $187M in assets under management (AUM), dropping by 84.01%.
- Central Index Key (CIK): 0001931118
Tip: Access up to 7 years of quarterly data
Positions held by Superstring Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Superstring Capital Management
Superstring Capital Management holds 45 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cidara Therapeutics Com New (CDTX) | 10.1 | $19M | +24% | 85k | 220.89 |
|
| Terns Pharmaceuticals (TERN) | 9.6 | $18M | -43% | 444k | 40.40 |
|
| Urogen Pharma (URGN) | 9.0 | $17M | +717% | 718k | 23.42 |
|
| Cogent Biosciences (COGT) | 7.0 | $13M | 366k | 35.52 |
|
|
| Dynavax Technologies Corp Com New (DVAX) | 4.3 | $8.1M | NEW | 526k | 15.38 |
|
| Sionna Therapeutics (SION) | 4.0 | $7.4M | NEW | 181k | 41.14 |
|
| Immunovant (IMVT) | 3.9 | $7.3M | -15% | 289k | 25.42 |
|
| Axsome Therapeutics (AXSM) | 3.7 | $6.8M | NEW | 37k | 182.64 |
|
| Savara (SVRA) | 3.2 | $6.0M | -23% | 995k | 6.03 |
|
| Mind Medicine Mindmed Com New (MNMD) | 3.0 | $5.7M | NEW | 425k | 13.39 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 2.9 | $5.4M | NEW | 981k | 5.50 |
|
| Ocular Therapeutix (OCUL) | 2.7 | $5.1M | NEW | 418k | 12.14 |
|
| Amicus Therapeutics (FOLD) | 2.7 | $5.0M | NEW | 353k | 14.24 |
|
| Cabaletta Bio (CABA) | 2.6 | $4.9M | +45% | 2.3M | 2.19 |
|
| United Therapeutics Corporation (UTHR) | 2.5 | $4.6M | NEW | 9.5k | 487.25 |
|
| Revolution Medicines (RVMD) | 2.3 | $4.4M | NEW | 55k | 79.65 |
|
| Belite Bio Sponsored Ads (BLTE) | 2.1 | $4.0M | NEW | 25k | 159.96 |
|
| Bright Minds Biosciences Com New (DRUG) | 2.0 | $3.7M | -12% | 47k | 78.04 |
|
| Zai Lab Adr (ZLAB) | 1.9 | $3.5M | 197k | 17.64 |
|
|
| Zenas Biopharma (ZBIO) | 1.6 | $3.0M | -13% | 83k | 36.31 |
|
| Cortexyme (QNCX) | 1.5 | $2.9M | NEW | 859k | 3.35 |
|
| Avalo Therapeutics Com New (AVTX) | 1.5 | $2.8M | -18% | 153k | 18.16 |
|
| Capricor Therapeutics Com New (CAPR) | 1.5 | $2.8M | NEW | 96k | 28.86 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 1.4 | $2.7M | NEW | 26k | 104.67 |
|
| Celldex Therapeutics Com New (CLDX) | 1.3 | $2.4M | NEW | 88k | 27.16 |
|
| Assembly Biosciences Com New (ASMB) | 1.2 | $2.2M | NEW | 65k | 34.01 |
|
| Oric Pharmaceuticals (ORIC) | 1.1 | $2.1M | +185% | 255k | 8.18 |
|
| Protara Therapeutics Com Stk (TARA) | 1.0 | $1.9M | 360k | 5.33 |
|
|
| Trevi Therapeutics (TRVI) | 1.0 | $1.9M | NEW | 148k | 12.52 |
|
| Tyra Biosciences (TYRA) | 0.8 | $1.5M | NEW | 59k | 26.29 |
|
| Travere Therapeutics (TVTX) | 0.8 | $1.5M | -29% | 38k | 38.21 |
|
| Miragen Therapeutics (VRDN) | 0.7 | $1.3M | NEW | 43k | 31.12 |
|
| Rezolute Com New (RZLT) | 0.6 | $1.2M | NEW | 514k | 2.36 |
|
| Dianthus Therapeutics (DNTH) | 0.6 | $1.1M | NEW | 26k | 41.21 |
|
| Spruce Biosciences Com New (SPRB) | 0.6 | $1.1M | NEW | 12k | 87.11 |
|
| Aardvark Therapeutics (AARD) | 0.5 | $912k | NEW | 70k | 13.12 |
|
| Genmab A/s Sponsored Ads (GMAB) | 0.5 | $898k | NEW | 29k | 30.80 |
|
| Palisade Bio (PALI) | 0.5 | $863k | NEW | 367k | 2.35 |
|
| Fulcrum Therapeutics (FULC) | 0.4 | $815k | NEW | 72k | 11.31 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.4 | $730k | NEW | 32k | 23.00 |
|
| Palatin Technologies Com New (PTN) | 0.3 | $523k | NEW | 34k | 15.38 |
|
| Inventiva Sa Ads (IVA) | 0.2 | $465k | NEW | 100k | 4.65 |
|
| Century Therapeutics (IPSC) | 0.2 | $461k | 463k | 0.99 |
|
|
| Biomea Fusion (BMEA) | 0.2 | $310k | 250k | 1.24 |
|
|
| Entera Bio SHS (ENTX) | 0.0 | $33k | NEW | 17k | 1.94 |
|
Past Filings by Superstring Capital Management
SEC 13F filings are viewable for Superstring Capital Management going back to 2023
- Superstring Capital Management 2025 Q4 filed Feb. 17, 2026
- Superstring Capital Management 2025 Q3 filed Nov. 14, 2025
- Superstring Capital Management 2025 Q2 filed Aug. 14, 2025
- Superstring Capital Management 2025 Q1 filed May 15, 2025
- Superstring Capital Management 2024 Q4 filed Feb. 14, 2025
- Superstring Capital Management 2024 Q3 filed Nov. 14, 2024
- Superstring Capital Management 2024 Q2 filed Aug. 14, 2024
- Superstring Capital Management 2024 Q1 filed May 15, 2024
- Superstring Capital Management 2023 Q4 filed Feb. 14, 2024